Everything That Happens Before the Needle Goes In

An odd chromatogram deserves to be re-prepared before it is re-interpreted. That is the practical conclusion, and it is worth stating first because the reasoning behind it is a list of things that happen between the vial and the detector without ever appearing on a document. Dissolve the material fresh, dilute it into weak solvent, either skip filtration or bracket it, and inject without delay. Should the result shift, preparation was the variable. Should it hold, the question returns to the material itself.

Solvent mismatch, the error with a visible signature

Take the most common preparation fault first, because it announces itself in the peak shape. Whenever the solvent holding the sample is stronger, meaning more organic, than the mobile phase at the gradient’s start, focusing at the head of the column fails to occur. The analyte sets off down the column straight away, distributed across the full width of the injection band.

Fronting, splitting or broadening follows, and the magnitude scales with how much volume was injected. Diluting into the starting mobile phase composition beforehand eliminates it entirely. So a distorted peak that tidies up once the sample is diluted in weaker solvent was telling you about the preparation, not about the material.

Getting the powder into solution

Before any of that, something has to dissolve the lyophilized material, and which solvent gets chosen is a decision rather than a formality. Water alone handles many sequences and defeats others. Strongly acidic peptides dissolve poorly at low pH; strongly basic ones dissolve poorly at high pH; amphipathic sequences may want a small fraction of organic solvent, or a short spell of gentle agitation.

Where dissolution has to be forced, the forcing carries its own cost. Sonication can drive local temperature up substantially and generate reactive species along the way, while heat speeds every degradation pathway the sequence is capable of. A sample that resisted dissolution and was made to dissolve anyway may no longer be the sample it was.

Losses on the way to the column

Surfaces take peptide out of solution, cationic sequences binding especially readily to glass and to certain plastics. Concentrated samples shrug this off. Dilute ones can lose a substantial share of what was weighed out.

Two things follow from that. Recovery can be poor with no degradation whatsoever having taken place, so a low apparent content is not automatically a content problem. And because adsorption is not uniform across species, an impurity that binds more or less avidly than the main component will distort the measured ratio between them. Low-binding vials help, as does adding a little organic solvent.

Filtration works the same way with a larger surface. Membranes bind peptide and protein, the quantity depending on membrane chemistry, on area and on concentration, and samples get filtered routinely to keep particulates off the column. The conventional remedy is to throw away the first portion of filtrate so that binding sites are saturated and whatever is collected afterwards has not been altered in composition. Omit that step, particularly with a dilute sample, and a measurable proportion of analyte disappears, sometimes selectively. Where the only goal is removing particulates, centrifugation avoids the whole issue.

Hours spent waiting in the tray

Injection sequences can run most of a day, which means the samples scheduled last have sat dissolved at the autosampler’s temperature for the entire run.

Give a peptide a fast degradation route and that is more than enough time. A free thiol oxidizes, an N-terminal glutamine cyclizes, a labile asparagine deamidates. First and last injections drawn from one solution can then return different impurity profiles, and the difference is a real chemical one rather than an instrumental artifact. Chilling the autosampler slows it down. Bracketing the run with repeat injections of the same sample detects it: divergence between the brackets means something changed inside the vial while the sequence ran.

Too much on the column

Overload saturates the stationary phase locally, and the peak fronts and broadens in response. Resolution between the main component and any impurity sitting close to it deteriorates exactly where resolution is most needed.

Fortunately the diagnosis is straightforward, because the effect depends on concentration. Halve the amount injected, re-run, and both the area should halve and the shape should improve. A shape that does not improve was never overloaded, and the broadening originates elsewhere.

Why the certificate is silent on all of it

Preparation is conventionally filed under internal method detail rather than reportable result. That is why a document will specify column and gradient while saying nothing at all about how the vial was dissolved or whether anything was filtered.

No criticism is implied by pointing this out; the convention is universal. It matters only because this is one of the places two laboratories analyzing a single lot can diverge with neither of them doing anything wrong, sitting alongside the mobile-phase and integration differences examined in why certificates disagree on purity. Further on the first decision of all: choosing a reconstitution solvent.